Introduction {#sec1}
============

Ischemic stroke (IS) is one of the leading causes of morbidity and mortality all over the world \[[@B1]\]. So far, the exact cause of IS remains ambiguous in spite of extensive investigations. Nevertheless, accumulating evidence suggests that genetic factors may play crucial parts in its pathogenesis. First, numerous genetic variants were found to be associated with an increased risk of IS by previous genetic association studies \[[@B2]--[@B4]\]. Second, screening of common causal variants was also proved to be a cost-efficient way to predict the individual risk of developing IS \[[@B5],[@B6]\]. Overall, these findings supported that genetic predisposition is crucial for the occurrence and development of IS.

Antisense non-coding RNA in the INK4 locus (*ANRIL*) is located on human chromosome 9p21, a region that has been repeatedly linked to atherosclerosis and its associated ischemic vascular diseases \[[@B7]\]. Previous studies demonstrated that the expression levels of several neighbor protein-encoding genes like cyclin-dependent kinase inhibitors 2A (*CDKN2A*), *CDKN2B* and methylthioadenosine phosphorylase (*MTAP*) are modulated by *ANRIL*. It was shown that the above-mentioned proteins were abundantly expressed in atherosclerotic lesions, and they could promote atherosclerosis by impacting vascular remodeling, thrombogenesis and plaque stability \[[@B8]\]. Additional, recent experimental analyses also showed that *ANRIL* could promote inflammation by inhibiting caspase recruitment domain family member (CARD) 8 and activating the NF-κB pathway \[[@B9]\]. Considering the critical role of *ANRIL* in regulating atherosclerosis and inflammation as well as the close relationship between these two processes and IS, it is believed that functional *ANRIL* variants may also be involved in the development of IS.

In the past decade, several studies have already investigated potential correlations between *ANRIL* variants and the risk of IS, yet the results of these studies were controversial \[[@B10],[@B11]\]. Thus, we performed the present meta-analysis to better evaluate the roles of *ANRIL* variants in IS.

Materials and methods {#sec2}
=====================

Literature search and inclusion criteria {#sec2-1}
----------------------------------------

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline \[[@B12]\]. The authors conducted a systematic search of PubMed, Medline and Embase to identify potentially related literatures published up to October 2018 using the following searching strategy: (antisense noncoding RNA in the INK4 locus OR CDKN2B antisense RNA OR ANRIL OR CDKN2B-AS long non-coding RNA) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (ischemic stroke OR cerebral infarction OR brain infarction OR cerebrovascular disease). Furthermore, the references of retrieved articles were also screened for other potentially relative studies.

To test the research hypothesis of this meta-analysis, included studies must meet all the following criteria: (a) case--control study on correlation between *ANRIL* variants and IS; (b) it provides genotypic and/or allelic frequency of *ANRIL* variants in cases and controls; (c) full text in English or Chinese available. Studies were excluded if one of the following criteria was fulfilled: (a) not related to *ANRIL* variants and IS; (b) case reports or case series; (c) abstracts, reviews, comments, letters and conference presentations. For duplicate reports, we only included the study with the largest sample size for analyses.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

The following data were extracted from included studies: (i) name of the first author; (ii) publication year; (iii) country and ethnicity; (iv) sample size; and (v) genotypic distribution of *ANRIL* variants in cases and controls. Additionally, the probability value (*P*-value) of Hardy--Weinberg equilibrium (HWE) was also calculated. When necessary, we wrote to the corresponding authors for raw data. We used the Newcastle--Ottawa scale (NOS) to evaluate the quality of eligible studies \[[@B13]\]. This scale has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality. Two reviewers conducted data extraction and quality assessment independently. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analyses {#sec2-3}
--------------------

All statistical analyses were achieved using Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate strength of associations, and *P*-values ≤0.05 were considered to be statistically significant. Between-study heterogeneities were evaluated with *I^2^* statistic. Random-effect models (REMs) would be used to pool the data if *I^2^* ≥ 50%. Otherwise, fixed-effect models (FEMs) would be employed for synthetic analyses. Subgroup analyses by ethnicity were subsequently performed. Sensitivity analyses were executed to test the stability of synthetic results. Funnel plots were used to assess publication biases.

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

We found 115 potential relative articles. Among these articles, a total of 18 eligible studies which met our inclusion criteria were included for synthetic analyses (see [Figure 1](#F1){ref-type="fig"}). The NOS score of eligible articles ranged from 7 to 8, which indicated that all included studies were of high quality. Baseline characteristics of included studies were shown in [Table 1](#T1){ref-type="table"} \[[@B10]\].

![Flowchart of study selection for the present study](bsr-39-bsr20182127-g1){#F1}

###### The characteristics of included studies for *ANRIL* variants and IS

  First author (year)              Country       Ethnicity   Sample size   Genotype distribution   Minor allele (%) Case/Control   *P*-value for HWE   NOS score   
  -------------------------------- ------------- ----------- ------------- ----------------------- ------------------------------- ------------------- ----------- ---
  **rs1333040**                    TT/TC/CC                                                                                                                        
  Akinyemi (2018) \[[@B10]\]       Nigeria       African     82/247        NA                      NA                              42.1%/42.9%         NA          7
  Cao (2016) \[[@B15]\]            China         Asian       569/541       267/247/55              256/225/60                      31.4%/31.9%         0.323       8
  Heckman (2013) \[[@B19]\]        U.S.A.        Mixed       264/373       93/127/44               130/179/64                      40.7%/41.2%         0.859       7
  Lin (2011) \[[@B23]\]            Taiwan        Asian       634/1352      324/259/51              649/573/130                     28.5%/30.8%         0.829       7
  Olsson (2011) \[[@B25]\]         Sweden        Caucasian   803/641       248/392/163             177/314/150                     44.7%/47.9%         0.639       8
  Xiong (2018) \[[@B26]\]          China         Asian       200/205       104/79/17               112/76/17                       28.3%/26.8%         0.425       8
  **rs1333049**                    GG/GC/CC                                                                                                                        
  Haslacher (2016) \[[@B18]\]      Austria       Caucasian   151/773       33/84/34                218/374/183                     50.3%/47.6%         0.402       7
  Lin (2011) \[[@B23]\]            Taiwan        Asian       642/1361      176/313/153             395/655/311                     48.2%/46.9%         0.213       7
  Xiong (2018) \[[@B26]\]          China         Asian       200/205       53/96/51                56/102/47                       49.5%/47.8%         0.966       8
  Yang (2018) \[[@B28]\]           China         Asian       550/549       162/266/122             176/273/100                     46.4%/43.1%         0.743       8
  **rs2383206**                    AA/AG/GG                                                                                                                        
  Ding (2009) \[[@B16]\]           China         Asian       991/1054      275/463/253             314/526/214                     48.9%/45.3%         0.816       8
  Hu (2009) \[[@B21]\]             China         Asian       352/423       97/188/67               154/191/78                      45.7%/41.0%         0.169       7
  Xiong (2018) \[[@B26]\]          China         Asian       200/205       56/96/48                61/98/46                        48.0%/46.3%         0.579       8
  Zee (2007) \[[@B29]\]            U.S.A.        Mixed       254/254       NA                      NA                              46.6%/46.3%         NA          7
  Zhang (2012) \[[@B30]\]          China         Asian       1190/1664     359/569/262             514/833/317                     45.9%/44.1%         0.529       8
  **rs2383207**                    GG/GA/AA                                                                                                                        
  Gschwendtner (2009) \[[@B17]\]   Germany       Caucasian   962/4260      NA                      NA                              41.1%/43.0%         NA          7
  Heckman (2013) \[[@B19]\]        U.S.A.        Mixed       264/373       64/131/69               105/169/99                      50.9%/49.2%         0.071       7
  Lin (2011) \[[@B23]\]            Taiwan        Asian       627/1349      288/274/65              568/609/172                     32.2%/35.3%         0.660       7
  Xiong (2018) \[[@B26]\]          China         Asian       200/205       92/89/19                103/80/22                       31.8%/30.2%         0.282       8
  Yang (2018) \[[@B28]\]           China         Asian       550/548       236/237/77              244/251/53                      35.5%/32.6%         0.317       8
  Zhang (2012) \[[@B30]\]          China         Asian       1190/1637     487/552/151             652/769/216                     35.9%/36.7%         0.649       8
  **rs10757274**                   GG/GA/AA                                                                                                                        
  Akinyemi (2018) \[[@B10]\]       Nigeria       African     82/247        NA                      NA                              14.8%/13.6%         NA          7
  Hu (2009) \[[@B21]\]             China         Asian       353/430       101/193/59              154/202/74                      44.1%/40.7%         0.579       7
  Luke (2009) \[[@B24]\]           Austria       Caucasian   503/784       117/247/139             216/414/154                     52.1%/46.0%         0.079       7
  Xiong (2018) \[[@B26]\]          China         Asian       200/205       55/94/51                62/96/47                        49.0%/46.3%         0.403       8
  Yamagishi (2009) \[[@B27]\]      U.S.A.        African     218/3281      141/64/13               2033/1085/163                   20.6%/21.5%         0.243       7
  Yamagishi (2009) \[[@B27]\]      U.S.A.        Caucasian   306/9575      77/170/59               2551/4743/2281                  47.1%/48.6%         0.405       7
  Zee (2007) \[[@B29]\]            U.S.A.        Mixed       254/254       NA                      NA                              49.4%/49.2%         NA          7
  Zhang (2012) \[[@B30]\]          China         Asian       1190/1664     341/556/293             492/842/330                     48.0%/45.1%         0.376       8
  **rs10757278**                   GG/GA/AA                                                                                                                        
  Akinyemi (2018) \[[@B10]\]       Nigeria       African     82/247        NA                      NA                              11.0%/12.6%         NA          7
  Bi (2015) \[[@B14]\]             China         Asian       116/118       38/49/29                56/47/15                        46.1%/32.6%         0.307       8
  Ding (2009) \[[@B16]\]           China         Asian       999/1055      378/431/190             384/497/174                     40.6%/40.0%         0.538       8
  Gschwendtner (2009) \[[@B17]\]   Germany       Caucasian   952/4262      NA                      NA                              50.5%/46.9%         NA          7
  Heckman (2013) \[[@B19]\]        U.S.A.        Mixed       263/374       78/139/46               103/190/81                      43.9%/47.1%         0.705       7
  Helgadottir (2008) \[[@B20]\]    New Zealand   Caucasian   705/15012     NA                      NA                              46.8%/43.3%         NA          7
  Lemmens (2009) \[[@B22]\]        Belgium       Caucasian   914/809       176/461/277             227/386/196                     55.5%/48.1%         0.207       8
  Olsson (2011) \[[@B25]\]         Sweden        Caucasian   834/665       222/415/197             191/342/132                     48.5%/45.6%         0.343       8
  Xiong (2018) \[[@B26]\]          China         Asian       200/205       53/95/52                59/99/47                        49.8%/47.1%         0.656       8
  Zhang (2012) \[[@B30]\]          China         Asian       986/1452      302/448/236             384/706/362                     46.7%/49.2%         0.298       8

Abbreviation: NA, Not available.

Overall and subgroup analyses {#sec3-2}
-----------------------------

To investigate potential correlations between *ANRIL* variants and the risk of IS, six studies about rs1333040 polymorphism (2552 cases and 3359 controls), four studies about rs1333049 polymorphism (1543 cases and 2888 controls), five studies about rs2383206 polymorphism (2987 cases and 3600 controls), six studies about rs2383207 polymorphism (3793 cases and 8372 controls), seven studies about rs10757274 polymorphism (3106 cases and 16440 controls) and ten studies about rs10757278 polymorphism (6051 cases and 24199 controls) were enrolled for analyses. Significant associations with the risk of IS were detected for rs2383206 (recessive model: *P*=0.002, OR = 1.22, 95%CI 1.08--1.38, *I^2^* = 0%, FEM; allele model: *P*=0.003, OR = 0.90, 95%CI 0.84--0.96, *I^2^* = 0%, FEM) and rs10757274 (allele model: *P*=0.006, OR = 0.91, 95%CI 0.86--0.97, *I^2^* = 25%, FEM) variants in overall analyses. Further subgroup analyses by ethnicity of participants revealed that rs2383206, rs10757274 and rs10757278 variants were all significantly correlated with the risk of IS in Asians. Moreover, rs10757278 polymorphism was also significantly correlated with the risk of IS in Caucasians (see [Table 2](#T2){ref-type="table"} and Supplementary Figure S1).

###### Overall and subgroup analyses for *ANRIL* variants and IS

  Polymorphisms    Population   Sample size   Dominant comparison   Recessive comparison   Additive comparison   Allele comparison                                                        
  ---------------- ------------ ------------- --------------------- ---------------------- --------------------- ----------------------- ---------- ----------------------- ------------- -----------------------
  **rs1333040**    Overall      2552/3359     0.22                  1.07 (0.96--1.20)      0.07                  0.86 (0.73--1.01)       0.98       1.00 (0.90--1.12)       0.07          1.08 (0.99--1.16)
                   Asian        1403/2098     0.50                  1.05 (0.91--1.20)      0.21                  0.86 (0.67--1.09)       0.95       1.00 (0.87--1.16)       0.28          1.06 (0.95--1.18)
  **rs1333049**    Overall      1543/2888     0.10                  0.89 (0.77--1.02)      0.20                  1.11 (0.95--1.29)       0.68       1.03 (0.90--1.17)       0.07          0.92 (0.84--1.01)
                   Asian        1392/2115     0.25                  0.91 (0.79--1.06)      0.13                  1.13 (0.96--1.34)       0.84       0.99 (0.86--1.13)       0.10          0.92 (0.84--1.02)
  **rs2383206**    Overall      2987/3600     0.05                  0.90 (0.80--1.00)      **0.002**             **1.22 (1.08--1.38)**   0.98       1.00 (0.83--1.20)       **0.003**     **0.90 (0.84--0.96)**
                   Asian        2733/3346     0.05                  0.90 (0.80--1.00)      **0.002**             **1.22 (1.08--1.38)**   0.98       1.00 (0.83--1.20)       **0.002**     **0.89 (0.83--0.96)**
  **rs2383207**    Overall      3793/8372     0.64                  1.02 (0.93--1.13)      0.79                  0.98 (0.85--1.13)       0.79       0.99 (0.90--1.09)       0.21          1.04 (0.98--1.10)
                   Asian        2567/3739     0.43                  1.04 (0.94--1.16)      0.99                  1.00 (0.76--1.32)       0.53       0.97 (0.87--1.07)       0.48          1.03 (0.95--1.11)
  **rs10757274**   Overall      3106/16440    0.07                  0.91 (0.82--1.01)      0.26                  1.14 (0.91--1.44)       0.95       1.01 (0.84--1.20)       **0.006**     **0.91 (0.86--0.97)**
                   Caucasian    809/10359     0.11                  0.86 (0.71--1.03)      0.80                  1.10 (0.54--2.21)       0.81       1.05 (0.71--1.53)       0.55          0.91 (0.67--1.23)
                   Asian        1743/2299     0.11                  0.89 (0.78--1.03)      **0.007**             **1.23 (1.06--1.44)**   0.80       1.04 (0.76--1.42)       **0.009**     **0.89 (0.81--0.97)**
  **rs10757278**   Overall      6051/24199    0.35                  0.90 (0.72--1.12)      0.10                  1.16 (0.97--1.37)       0.20       0.95 (0.87--1.03)       0.05          0.91 (0.82--1.00)
                   Caucasian    3405/20748    0.12                  0.74 (0.51--1.08)      **0.001**             **1.31 (1.12--1.54)**   0.70       1.03 (0.89--1.18)       **\<0.001**   **0.85 (0.80--0.90)**
                   Asian        2301/2830     0.89                  0.98 (0.77--1.26)      0.22                  1.17 (0.91--1.50)       **0.03**   **0.88 (0.79--0.99)**   0.40          0.92 (0.76--1.11)

Abbreviation: NA, Not available.

The values in bold represent that there are statistically significant differences between cases and controls.

All investigated *ANRIL* variants contain a major allele (M) and a minor allele (m). In the current meta-analysis, dominant model is defined as MM versus Mm + mm, recessive model is defined as mm versus MM +Mm, Additive model is defined as Mm versus MM + mm, and the allele model is defined as M versus m.

Sensitivity analyses {#sec3-3}
--------------------

We performed sensitivity analyses to examine whether studies that deviated from HWE would impact the results of synthetic analyses. No alterations of results were detected in sensitivity analyses when we omitted one specific study each time, which suggested that our pooled results were statistically stable and reliable.

Publication biases {#sec3-4}
------------------

Funnel plots were used to estimate publication biases. We did not find obvious asymmetry of funnel plots in any comparisons, which suggested that our findings were unlikely to be influenced by severe publication biases (see Supplementary Figure S2).

Discussion {#sec4}
==========

To the best of our knowledge, this is the most comprehensive meta-analysis on associations between *ANRIL* variants and the risk of IS. Our overall and subgroup analyses suggested that rs2383206, rs10757274 and rs10757278 variants were all significantly associated with an increased risk of IS in Asians. In addition, rs10757278 polymorphism was also significantly associated with an increased risk of IS in Caucasians. As shown in Supplementary Figure S1, for rs1333040, rs1333049, rs2383206 and rs2383207 variants, between-study heterogeneities were trivial, and thus pooled analyses were mainly performed with FEM. For rs10757274 and rs10757278 variants, however, obvious between-study heterogeneities were observed for recessive and additive comparisons, and thus REMs were employed for these analyses.

There are several points that need to be addressed about this meta-analysis. First, the exact function of ANRIL is still unclear, and therefore the underlying mechanisms of our positive findings need to be investigated by future investigations. Second, the pathogenic mechanism of IS is rather complex, and it is unlikely that a single genetic variant can significantly contribute to its development. So to better illustrate potential correlations of certain genetic variants with IS, we strongly recommend further studies to perform haplotype analyses and explore potential gene--gene interactions. Third, it is also worth noting that according to our findings, the associations between *ANRIL* variants and IS may be ethnic-specific, and this may explain why inconsistent results were observed in included original studies, especially when these studies were performed in different populations.

As with all meta-analysis, the present study certainly has some limitations. First, our results were derived from unadjusted analyses, and lack of further adjusted analyses for age, gender, smoking status and co-morbidity conditions (such as hypertension, diabetes, dyslipidemia, coronary artery disease and peripheral artery disease) may impact the reliability of our findings since the above-mentioned variables may also impact the individual susceptibility to IS \[[@B31],[@B32]\]. Second, obvious heterogeneities were still found in several subgroup comparisons for rs10757274 and rs10757278 variants, which indicated that the controversial results of included studies could not be fully explained by differences in ethnic background, and other baseline characteristics of participants may also contribute to between-study heterogeneities \[[@B33],[@B34]\]. Third, associations between *ANRIL* variants and IS may also be modified by gene--environment interactions. However, most eligible studies ignore these potential interactions, which impeded us to perform relevant analyses accordingly \[[@B35],[@B36]\]. On account of above-mentioned limitations, our findings should be cautiously interpreted.

Conclusions {#sec5}
===========

In conclusion, our meta-analysis suggested that rs2383206, rs10757274 and rs10757278 variants may impact individual susceptibility to IS in Asians. Moreover, rs10757278 polymorphism may also impact individual susceptibility to IS in Caucasians. However, considering that the sample sizes of several comparisons were still relatively small, further well-designed studies with larger sample sizes are still warranted to confirm our findings.
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